Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	15,535	14,343	14,202	13,117	12,173	16,072
Revenue Growth	9.29%	0.99%	8.27%	7.76%	-24.26%	89.14%
Gross Profit Gross Profit Growth	6,906	6,392	7,100	6,862	7,020	10,774
Operating Income Operating Income Growth	4,174	3,702	4,145	4,233	4,994	8,995
Net Income Net Income Growth	4,329	4,505	4,413	3,954	4,338	8,075
Earnings Per Share EPS Growth	40.43	41.48	38.34	34.77	38.22	71.97
EPS Growth	1.92%	8.19%	10.27%	-9.03%	-46.89%	135.81%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Product Sales Net Product Sales Growth	6,439	6,309	7,629	7,078	6,894	12,117
Total Collaboration Total Collaboration Growth	8,294	7,331	6,058	5,503	4,914	3,673
Other Product Other Product Growth	801.3	702.6	515	536.1	365.1	281.2
Revenue (Total) Revenue (Total) Growth	15,535	14,343	14,202	13,117	12,173	16,072

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	17,823	18,866	17,913	16,241	14,334	12,533
Total Debt Total Debt Growth	2,707	2,973	2,939	2,791	2,770	2,700
Net Cash (Debt) Net Cash Growth	15,116	15,893	14,974	13,451	11,565	9,833
Net Cash Growth	1.98%	6.14%	11.32%	16.31%	17.61%	144.18%
Net Cash Per Share Net Cash Per Share Growth	141.21	146.35	130.09	118.30	101.89	87.64

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	4,681	4,979	4,421	4,594	5,015	7,081
Capital Expenditures CapEx Growth	-920.9	-898.4	-755.9	-718.6	-590.1	-551.9
Free Cash Flow Free Cash Flow Growth	3,760	4,081	3,665	3,875	4,425	6,529
Free Cash Flow Growth	-2.42%	11.35%	-5.44%	-12.42%	-32.23%	225.90%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	44.46%	44.57%	49.99%	52.32%	57.67%	67.04%
Operating Margin	26.87%	25.81%	29.19%	32.27%	41.03%	55.97%
Pretax Margin	33.25%	36.47%	33.66%	32.01%	39.91%	58.03%
Profit Margin	27.87%	31.41%	31.07%	30.14%	35.64%	50.24%
FCF Margin	24.21%	28.45%	25.80%	29.54%	36.35%	40.63%

Dividends

Chart

Fiscal Year	Current	FY 2025
Period Ending	Oct 8, 2026	Dec 31, 2025
Dividend Per Share Dividend Per Share Growth	3.760	3.520
Dividend Per Share Growth	0%	-
Dividend Yield	0.51%	0.46%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 8, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	18.35	17.58	17.37	23.63	17.76	8.18
Forward PE	11.90	17.11	15.19	19.36	17.29	11.00
P/FCF Ratio	19.71	19.41	20.91	24.10	17.42	10.11
PS Ratio	4.77	5.52	5.40	7.12	6.33	4.11

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Jul 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Oct 7, 2026

Data Sources Report a data error